PRCT
PRCT
US74276L1052
PROCEPT BioRobotics Corporation
Loading chart...

Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Latest News

Related stocks

LMRI
LMRI • United States
Lumexa Imaging Holdings, Inc.
10.54 USD
1.01B USD
IRMD
IRMD • United States
iRadimed Corporation
87.45 USD
1.12B USD 1Y +11.7%
BBNX
BBNX • United States
Beta Bionics, Inc.
17.63 USD
951.07M USD 1Y -21.2%
CBLL
CBLL • United States
CeriBell, Inc.
23.63 USD
906.87M USD 1Y +89.1%
CNMD
CNMD • United States
CONMED Corporation
44.42 USD
1.33B USD 1Y -3%
QDEL
QDEL • United States
QuidelOrtho Corporation
13.42 USD
920.28M USD 1Y -55.5%
VREX
VREX • United States
Varex Imaging Corporation
18.46 USD
783.88M USD 1Y +56.9%
IART
IART • United States
Integra LifeSciences Holdings C
13.44 USD
1.05B USD 1Y -9.5%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
64.4% p.a.
Max Drawdown (5Y)
-83.2%
Sharpe Ratio (5Y)
-0.27
Beta Factor
0.92
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (64.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -83.2% in the extended horizon.
ende